Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has announced that its investigational compound has entered into Phase II clinical stage in the US and Europe for treatment of venous or arterial thromboembolism.
Subscribe to our email newsletter
TAK-442 is an oral selective and direct competitive inhibitor of activated Factor X (FXa). As Factor Xa plays a critical role in the blood coagulation cascade, inhibition of FXa is expected to result in interruption of either venous or arterial thromboembolism, such as pulmonary embolism, cerebral infarction, etc.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “We are pleased with the progress of TAK-442’s development stage into Phase II since this compound is expected to enhance our franchise of lifestyle-related diseases, which is one of four core therapeutic areas, such as cardiovascular and metabolic diseases including diabetes. We will vigorously conduct development activities in order to bring this novel treatment option to the patients as early as possible.”